Next Touch: BridGene Biosciences $28M Pipeline Trigger

BridGene just closed $28M Series B. Ping Cao needs chemoproteomics & clinical ops scale. Grab this battle card for your next touch and fill your pipeline fast.

Published on


Do not index
Do not index

๐Ÿš€ Battle Card: BridGene Biosciences

Quick trigger:
ย 
๐Ÿ‘ค Decision Maker in the News
ย 
๐Ÿ’ก Why It Matters
  • This funding supercharges BGC-515 clinical development and scales IMTACโ„ข screening for next-gen small molecules. โ†’ Source
ย 
๐ŸŽฏ Core Pain Point
  • Data bottlenecks in chemoproteomics delay candidate ID
  • Budget pressures for scaling clinical and R&D ops
ย 
๐Ÿ’ฐ What to Pitch
  • Primary: Integrated chemoproteomics informatics platform โ†’ accelerates binding site discovery by 30%
  • Expansion: Clinical development management solution โ†’ streamlines multicenter trial workflows
ย 
๐Ÿ—บ๏ธ Quick Context
  • HQ: San Jose, CA
  • Employees: โ‰ˆ 75
  • Rev: โ‰ˆ $3M
ย 

๐Ÿคผ Competitive Intel

Which other vendors youโ€™ll probably face to win BridGene Biosciencesโ€™s business.
ย 
  • Benchling โ€” R&D Cloud Platform
    • Unique edge: Unified LIMS & ELN for bio teams
    • Evaluated by Head of R&D for collaboration
    • benchling.com
  • Dotmatics โ€” Scientific Informatics
    • Unique edge: Comprehensive chemistry & biology data management
    • Evaluated by CSO for platform depth
    • dotmatics.com
  • Veeva Systems โ€” Clinical Trial Management
    • Unique edge: Compliance-focused CTMS
    • Evaluated by Head of Clinical Ops for trial readiness
    • veeva.com
ย 

โœ… Do-Now Checklist

Connect with Ping Cao on email to discuss the BridGene Biosciences sales trigger
Generate email + DM using the BridGene Biosciences sales trigger to showcase streamlined workflows
Schedule follow-ups in CRM (Day 3 & Day 10)
ย 

Next Step

Get BridGene Biosciences sales trigger intel like this dailyโ€”no fluff, all pipeline. Subscribe to NewsletterForLeads
ย 

๐Ÿง  Copy My Prompt for Personalized Cold Outreach

โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€
โœ๏ธ YOUR COMPANY
โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€
OUR_COMPANY   = โ‘<your company>โ‘
OFFER_BRIEF   = โ‘Integrated chemoproteomics informatics platformโ‘
PROOF_METRIC  = โ‘accelerates binding site discovery by 30%โ‘
CTA_STYLE     = โ‘quick_callโ‘
TONE          = โ‘friendlyโ‘

โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€
๐Ÿ“Œ TARGET COMPANY
โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€
NAME        = Ping
COMPANY     = BridGene Biosciences
DEPT        = R&D
SIZE        = 75
BOTTLENECK  = data bottlenecks in chemoproteomics delay candidate ID
EVENT       = $28M Series B+ financing round
DETAIL      = $28M Series B+ financing
PAIN        = Data bottlenecks in chemoproteomics delay candidate ID
SRC         = https://vcnewsdaily.com/bridgene-biosciences/venture-capital-funding/zgjhqmkphm
SIM_CO      = Benchling
WIN_METRIC  = accelerated binding site discovery by 30%
NEXT_SIZE   = 150
EMP_EST     = โ‰ˆ 75
REV_EST     = โ‰ˆ $3M

โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€
TASK FOR CHATGPT
โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€
Role: โ€œNewsletterForLeads SDR-Assistโ€.

Validate any โ‰ˆ guesses via SRC.

EMAIL  (keep breaks):
Subject: 75-person R&D

Pingโ€”noticed your R&D team is โ‰ˆ 75.

Thatโ€™s when data bottlenecks in chemoproteomics delay candidate ID slows growth.

We helped Benchling fix this with Integrated chemoproteomics informatics platform.

Result: accelerated binding site discovery by 30%.  
Quick call?

PSโ€”next bottleneck hits โ‰ˆ 150.

DM โ‰ค45 words, TONE:
Saw your post about $28M Series B+ financing โ€” Data bottlenecks in chemoproteomics delay candidate ID.  
Integrated chemoproteomics informatics platform. accelerates binding site discovery by 30%.  
Quick chat?

Join other 3200+ marketers now!

Ready to take the next big step for your business?

Subscribe